Sofalcone

Sofalcone

SCHEMBL40766

CC(C)=CCOc1ccc(C=CC(=O)c2ccc(OCC=C(C)C)cc2OCC(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
NR1I2 O75469 1/20 1.00
LMNA P02545 1/20 1.00
PGR P06401 1/20 1.00
ADRB2 P07550 1/20 1.00
ADRB1 P08588 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
HPGD P15428 1/20 1.00
CNR1 P21554 1/20 1.00
TBXA2R P21731 1/20 1.00
SLC6A2 P23975 1/20 1.00
AGTR1 P30556 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRD1 P41143 1/20 1.00
OPRK1 P41145 1/20 1.00
BLM P54132 1/20 1.00
SLC6A3 Q01959 1/20 1.00
ALOX5 P09917 4/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sofalcone SCHEMBL30383975 1.00 MAPT (1.00) MAPTMEN1KMT2ANR1I2LMNA
Sofalcone SCHEMBL25214686 1.00 MAPT (1.00) MAPTMEN1KMT2ANR1I2LMNA
Sofalcone SCHEMBL24786 1.00 MAPT (1.00) MAPTMEN1KMT2ANR1I2LMNA
Sofalcone SCHEMBL29363342 1.00 MAPT (1.00) MAPTMEN1KMT2ANR1I2LMNA
SCHEMBL9364195 0.99 MAPT (0.98) MAPTMEN1KMT2ANR1I2LMNA
Sofalcone SCHEMBL7842101 0.99 MAPT (0.98) MAPTMEN1KMT2ANR1I2LMNA
SCHEMBL9364183 0.99 MAPT (0.98) MAPTMEN1KMT2ANR1I2LMNA
SCHEMBL30382974 0.99 MAPT (0.98) MAPTMEN1KMT2ANR1I2LMNA
Sofalcone SCHEMBL10888696 0.96 MAPT (0.92) MAPTMEN1KMT2ANR1I2LMNA
SCHEMBL9368121 0.94 MAPT (0.89) MAPTMEN1KMT2ANR1I2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US claimed
WO-2025264604-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2025-12-26 WO claimed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US claimed
EP-4580612-A1 USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-09 EP claimed
US-20250090565-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YewSavin, Inc. (US) 2025-03-20 US claimed
CN-118235758-B Adipose-derived mesenchymal stem cell cryopreservation liquid and application thereof 吉林省微渺医疗科技有限公司 2025-02-28 CN claimed
CN-113995723-B Preparation method of sofalcel freeze-dried powder injection and product and application thereof 浙江普洛家园药业有限公司 2025-02-18 CN claimed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO claimed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP claimed
CN-118235758-A Adipose-derived mesenchymal stem cell cryopreservation liquid and application thereof 吉林省微渺医疗科技有限公司 2024-06-25 CN claimed
US-6103765-A Methods for treating male erectile dysfunction ANDROSOLUTIONS, INC. (US) 2000-08-15 US claimed
EP-1005336-A1 IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTILE DYSFUNCTION Androsolutions, Inc. (US) 2000-06-07 EP claimed
US-5908824-A DISPERSED HOMOGENEOUSLY IN AND ADSORBED HOMOGENEOUSLY ONTO A MUCOSA PROTECTING AND/OR TISSUE REPAIRING AGENT DOTT RESEARCH LABORATORY (JP) 1999-06-01 US claimed
WO-1999002147-A1 IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTILE DYSFUNCTION ANDROSOLUTIONS, INC. (US) 1999-01-21 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
EP-0770390-A1 Nasally administrable compositions containing physiologically active peptides DOTT RESEARCH LABORATORY (JP) 1997-05-02 EP claimed
US-5457128-A Topical preparation for healing wounds of the skin DOTT LIMITED COMPANY (JP) 1995-10-10 US claimed
EP-0591546-A1 EXTERNAL PREPARATION FOR CURING DAMAGE TO SKIN DOTT LIMITED COMPANY (JP) 1994-04-13 EP claimed
US-4085135-A ANTIULCER TAISHO PHARMACEUTICAL CO., LTD. (JA) 1978-04-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885MEN1 3367/4885KMT2A 2792/4885
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME SQSTM1, BECN1, CUTA MAPT 411/4885MEN1 3254/4885KMT2A 3682/4885
US-20250090565-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, TFPI, SERPINE1 MAPT 3522/4885MEN1 2669/4885KMT2A 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.